CYP2C9、CYP2C19、CYP3A4基因多态性对磺脲类降糖药代谢的影响  

Effect of CYP2C9,CYP2C19,CYP3A4 polymorphism on metabolism of sulfonyluea antidiabetic drugs

作　　者：李赟 何芳[1] 曾彩雯[1] 刘林林[1] 夏春华[1] 

机构地区：[1]南昌大学医学院临床药理研究所,江西南昌330006 [2]江西护理职业技术学院,江西南昌330201

出　　处：《中国临床药理学与治疗学》2012年第5期582-587,共6页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：国家自然科学基金(81060275;81160411);国家十二五重大专项(2011ZX09302-007-03);江西省自然科学基金(2009GZY0141)

摘　　要：磺脲类口服降糖药在人体内主要经过肝脏代谢。肝脏中的细胞色素氧化酶P450是一种重要的药物代谢酶系统,在人群中存在基因多态性,导致药物疗效和不良反应在个体间存在着较大的差异。本文将对CYP450中的几种重要的代谢酶亚型CYP2C9、CYP2C19、CYP3A4的基本结构、基因多态性、种族差异及其对磺脲类降糖药代谢的影响作一综述。Sulfonylurea oral antidiabetic drugs were mainly metabolized by hepatic cyto- chrome P450 in human. Cytochrome P450 is one kind of important drug metabolizing enzymes in human and exhibits genetic polymorphism, which usually results in the difference of efficacy and adverse reaction among individuals. The pur- pose of this paper was to review the basic struc-ture, genetic polymorphism and ethnic difference of CYP2Cg, CYP2C19, CYP3A4 and the influ ence to sulfonylurea metabolism.

关 键 词：CYP2C9 CYP2C19 CYP3A4 磺脲类降糖药 药物代谢 

分 类 号：R968[医药卫生—药理学]